A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4

NCT02091999 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
213
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Astellas Pharma Global Development, Inc.

Collaborators